Dr. David H. Hunter, M.D.
Neurology (Behavioral Neurology & Neuropsychiatry Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 234
Licensed in Texas since 2016, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: University of Texas Medical School at Houston
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Behavioral Neurology & Neuropsychiatry Physician primary
TX license Q6946 (first issued 2016; active) -
Neurology Physician
TX license Q6946 (first issued 2016; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- Memorial Hermann - Texas Medical Center Houston, TX
- Memorial Hermann Memorial City Hospital Houston, TX
- Memorial Hermann Sugar Land Hospital Sugar Land, TX
- Christus Southeast Texas- St Elizabeth Beaumont, TX
Medical groups
- Ut Physicians (213 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 234
- Services billed
- 215,237
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 158 | 120 |
| Established patient office or other outpatient visit, 40-54 minutes | 113 | 96 |
| New patient office or other outpatient visit, 60-74 minutes | 101 | 101 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Houston, TX | 728 |
| Memantine Hcl Other prescribers in Houston, TX | 560 |
| Nuplazid (pimavanserin tartrate) | 242 |
| Escitalopram Oxalate Other prescribers in Houston, TX | 152 |
| Galantamine Hbr Other prescribers in Houston, TX | 86 |
| Rivastigmine Other prescribers in Houston, TX | 84 |
| Mirtazapine Other prescribers in Houston, TX | 82 |
| Quetiapine Fumarate Other prescribers in Houston, TX | 71 |
| Gabapentin Other prescribers in Houston, TX | 56 |
| Clonazepam Other prescribers in Houston, TX | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 7 payments worth $231 in total to this clinician.
| Acadia Pharmaceuticals Inc | $186 |
|---|---|
| Lilly USA, LLC | $45.40 |
| Food and Beverage | $231 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $767,463 in research payments for these studies, mostly to the institutions running them.
- A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT05026866 - Open-label rollover study for continuing valbenazine administration for the treatment of chorea associated with huntington disease
Neurocrine Biosciences, Inc. - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - ACP-204 in Adults With Alzheimer's Disease Psychosis
Acadia Pharmaceuticals Inc · Recruiting · NCT06159673 - A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company · Active, not recruiting · NCT05738486 - ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Acadia Pharmaceuticals Inc · Enrolling by invitation · NCT06194799
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.